Effect of pioglitazone combined with simvastatin on the CD40-CD40 ligand system in rabbits with atherosclerosis

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 2, 2015, Pages 322-327

  Xue, L ^a,b   Ozhu, X H ^a   Yang, X F ^a   Bao, X C ^a   Gao, X Q ^a   Qiu, Y H ^a   Wu, Z ^a   Ji, X P ^b   Li, H W ^c  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Central Hospital of Panjin City   (China)

Author keywords

Atherosclerosis; Cd40 cd40 ligand; Pioglitazone; Simvastatin

Indexed keywords

C REACTIVE PROTEIN; CD40 CD40 LIGAND; CD40 LIGAND; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; CD40 ANTIGEN; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RABBIT; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; MALE; MEASUREMENT; MICROSCOPY; NONHUMAN; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ATHEROSCLEROSIS; BLOOD; RABBIT; RANDOMIZATION;

ANIMALS; ANTIGENS, CD40; ATHEROSCLEROSIS; CD40 LIGAND; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; RABBITS; RANDOM ALLOCATION; SIMVASTATIN; THIAZOLIDINEDIONES;

EID: 84938893757     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. LUSIS AJ, MAR R, PAJUKANTA P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004; 5: 189-218.
2. GARGALOVIC PS, IMURA M, ZHANG B, GHARAVI NM, CLARK MJ, PAGNON J, YANG WP, HE A, TRUONG A, PATEL S, NELSON SF, HORVATH S, BERLINER JA, KIRCHGESSNER TG, LUSIS AJ. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U SA 2006; 103: 2741-2746.
3. TUTTOLOMONDO A, DI-RAIMONDO D, PECORARO R, ARNAO V, PINTO A, LICATA G. Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012; 18: 4266-4288.
4. BORCHERDING F, NITSCHKE M, HUNDORFEAN G, RUPP J, VON-SMOLINSKI D, BIEBER K, VAN-KOOTEN C, LEHNERT H, FELLERMANN K, BÜNING J. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inlammatory bowel disease. Am J Pathol 2010; 17: 1816-1827.
5. INWALD DP, MCDOWALL A, PETERS MJ, CALLARD RE, KLEIN NJ. CD40 is constitutively expressed onpLatelets and pmwides a novel mechanism for platelet activation. Cir Res 2003; 92 1041-1048.
6. TOUSOULIS D, ANDROULAKIS E, PAPAGEORGIOU N, BRIASOULIS A, SIASOS G, ANTONIADES C, STEFANADIS C. From atherosclerosis to acute coronary syndromes: The role of soluble CD40 ligand. Trends Cardiovasc Med 2010; 20: 153-164.
7. OGASAWARA D, SHITE J, SHINKE T, WATANABE S, OTAKE H, TANINO Y, SAWADA T, KAWAMORI H, KATO H, MIYOSHI N, HIRATA K. Pioglitazone reduces the necroticcore component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009; 7: 343- 351.
8. GARGALOVIC PS, IMURA M, ZHANG B, GHARAVI NM, CLARK MJ, PAGNON J, YANG WP, HE A, TRUONG A, PAL-TEL S, NELSON SF, HORVATH S, BERLINER JA, KIRCHGESSNER TG, LUSIS AJ. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A 2006; 103: 12741-12746.
9. TOUSOULIS D, ANDROULAKIS E, PAPAGEORGIOU N, BRIASOULIS A, SIASOS G, ANTONIADES C, STEFANADIS C. From atherosclerosis to acute coronary syndromes: The role of soluble CD40 ligand. Trends Cardiovasc Med 2010; 20: 153-164.
10. ANTONIADES C, BAKOGIANNIS C, TOUSOULIS D, ANTONOPOULOS AS, STEFANADIS C. The CD40/CD40 ligand system: linking inlammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-677.
11. WIERZBICKI AS. Lipid-altering therapies and the progression of atherosclerotic disease. Cardiovasc Intervent Radiol 2007; 30: 155-160.
12. ROBLES-CARRILLO L, MEYER T, HATFIELD M, DESAI H, DÁVILA M, LANGER F, AMAYA M, GARBER E, FRANCIS JL, HSU YM, AMIRKHOSRAVI A. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010; 185: 1577-1583.
13. WANG JH, ZHANG YW, ZHANG P, DENG BQ, DING S, WANG ZK, WU T, WANG J. CD40 ligand as a potential biomarker for atherosclerotic instability. Neurol Res 2013; 35: 693-700.
14. CLARK RB, BISHOP-BAILEY D, ESTRADA-HERNANDEZ T, HLA T, PUDDINGTON L, PADULA SJ. The nuclear receptor PPAR and immunoregulation: PPAR?mediates inhibition of helper T cell responses. J Immunol 2000; 3: 1364-1371.
15. PAMUKCU B, LIP GY, SNEZHITSKIY V, SHANTSILA E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43: 331-340.
16. JUNG UJ, TORREJON C, CHANG CL, HAMAI H, WORGALL TS, DECKELBAUM RJ. Fatty acids regulate endothelial lipase and inflammatory markers in macrophages and in mouse aorta: A role for PPAR Arterioscler Thromb Vasc Biol 2012; 32: 2929-2937.
17. CHANG L, VILLACORTA L, LI R, HAMBLIN M, XU W, DOU C, ZHANG J, WU J, ZENG R, CHEN YE. Loss of perivascular adipose tissue on peroxisome proliferator- Activated receptor-?deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation 2012; 126: 1067-1078.
18. CHEN Y, ZHANG S, PENG G, YU J, LIU T, MENG R, LI Z, ZHAO Y, WU G. Endothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: pleiotropic and dose-dependent effect on tumor vascular stabilization. Int J Oncol 2013; 42: 1325-1336.
19. BERMAN JP, FARKOUH ME, ROSENSON RS. Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs 2013; 18: 193-205.
20. LIBBY P, SASIELA W. Plaque stabilization: Can we turn theory into evidence? Am J Cardiol 2006; 98: 26P-33P.